Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | TSPO | P30536 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.60 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 2/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608765 | 0.86 | GRM5 (0.64) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607805 | 0.81 | GRM5 (0.67) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608971 | 0.81 | GRM5 (0.61) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607850 | 0.80 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2174868 | 0.79 | GRM5 (0.49) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608787 | 0.78 | GRM5 (0.81) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL610471 | 0.78 | GRM5 (0.70) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608301 | 0.77 | GRM5 (0.70) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609930 | 0.77 | GRM5 (0.67) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609640 | 0.77 | GRM5 (0.70) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241260-A9 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2022-08-04 | — | — | US | claimed |
| US-20210052567-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2021-02-25 | — | — | US | claimed |
| US-20190216789-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2019-07-18 | — | — | US | claimed |
| US-20170202819-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG | 2017-07-20 | — | — | US | claimed |
| US-20150140087-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN-LA ROCHE INC. | 2015-05-21 | — | — | US | claimed |
| EP-2808022-A1 | Pharmaceutical compositions of metabotropic glutamate 5 receptor (MGLU5) antagonists | F. Hoffmann-La Roche AG (CH) | 2014-12-03 | — | — | EP | claimed |
| EP-2603206-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | claimed |
| EP-2603203-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | claimed |
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | claimed |
| WO-2012019989-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | claimed |
| WO-2012019990-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | claimed |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| CN-1960984-B | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | claimed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | claimed |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | US | claimed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | claimed |
| CN-1960984-A | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | claimed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2025-03-06 | — | — | US | disclosed |
| US-20220241260-A9 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2022-08-04 | — | — | US | disclosed |
| US-20210052567-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2021-02-25 | — | — | US | disclosed |
| US-20190216789-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20170202819-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG | 2017-07-20 | — | — | US | disclosed |
| US-20150140087-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN-LA ROCHE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2808022-A1 | Pharmaceutical compositions of metabotropic glutamate 5 receptor (MGLU5) antagonists | F. Hoffmann-La Roche AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-2603206-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| EP-2603203-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2012019989-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012019990-A2 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | disclosed |
| CN-1960984-B | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | US | disclosed |
| WO-2009024491-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-1960984-A | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20190216789-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1493/4885ADRB3 3062/4885 |
| US-20170202819-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | GRM5, HRH2, GRPR | GRM5 1/4885KCNH2 1043/4885ADRB3 533/4885 |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1554/4885ADRB3 2864/4885 |
| US-20220241260-A9 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20150140087-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20210052567-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.